替格瑞洛联合氢氯吡格雷及阿司匹林在冠心病介入治疗患者中的应用研究  

Application of ticagrelor combined with clopidogrel and aspirin in interventional treatment of coronary heart disease patients

作　　者：周伟娟 程鹏 Zhou Wei-juan;Cheng Peng(Department of Cardiology,Biyang People's Hospital,Biyang 463700,Henan,China)

机构地区：[1]泌阳县人民医院心内科,河南泌阳463700

出　　处：《四川生理科学杂志》2025年第3期676-678,共3页

摘　　要：目的:探讨替格瑞洛联合氢氯吡格雷及阿司匹林对经皮冠状动脉介入治疗(Percutaneous Coronary Intervention,PCI)术后冠心病患者的影响。方法:选取2021年4月至2023年4月于我院接受PCI治疗的86例冠心病患者作为研究对象,按照随机数字表法分为对照组和观察组,各43例。对照组于术后采用氢氯吡格雷及阿司匹林治疗,观察组在对照组的基础上加用替格瑞洛,两组均连续治疗3 m。比较两组临床疗效、血脂、炎性因子水平及心血管不良事件(Major Adverse Cardiovascular Events,MACE)发生情况。结果:治疗后,观察组三酰甘油(Triglyceride,TG)、总胆固醇(Total Cholesterol,TC)、低密度脂蛋白胆固醇(Low density protein Cholesterol,LDL-C)水平、肿瘤坏死因子-α(Tumor Necrosis Factor,TNF-α)、C反应蛋白(C-Reactive Protein,CRP)水平、以及MACE总发生率明显低于对照组(P<0.05);观察组高密度脂蛋白胆固醇(High Density lipoprotein Cholesterol,HDL-C)水平明显高于对照组(P<0.05)。结论:替格瑞洛联合双抗治疗冠心病患者效果明确,利于改善患者PCI术后血脂指标,降低其炎性因子水平,减少MACE发生率,预后效果良好。Objective:To explore the impact of ticagrelor combined with clopidogrel hydrochloride and aspirin on patients with coronary heart disease after percutaneous coronary intervention(PCI).Methods:A total of 86 patients with coronary heart disease who received PCI treatment in our hospital from April 2021 to April 2023 were selected as the research objects,and were divided into a control group and an observation group according to the random number table method,with 43 cases in each group.The control group was treated with clopidogrel hydrochloride and aspirin after surgery,and the observation group was treated with ticagrelor on the basis of the control group.Both groups were treated continuously for 3 months.The clinical efficacy,blood lipid,inflammatory factor levels and the occurrence of major adverse cardiovascular events(MACE)were compared between the two groups.Results:After treatment,the levels of triglyceride(TG),total cholesterol(TC),low-density lipoprotein cholesterol(LDL-C),tumor necrosis factor-α(TNF-α),C-reactive protein(CRP),and the total incidence of MACE in the observation group were significantly lower than those in the control group(P<0.05);the level of high-density lipoprotein cholesterol(HDL-C)in the observation group was significantly higher than that in the control group(P<0.05).Conclusion:Ticagrelor combined with dual antiplatelet therapy has a definite effect on patients with coronary heart disease,which is beneficial to improving the blood lipid index of patients after PCI,reducing the level of inflammatory factors,and reducing the incidence of MACE,with good prognosis.

关 键 词：冠心病 经皮冠状动脉介入 替格瑞洛 血脂 炎性因子 

分 类 号：R54[医药卫生—心血管疾病]